Cargando…

Indirect adjusted comparison of 6-month clinical outcomes between esketamine nasal spray and other real-world polypharmacy treatment strategies for treatment resistant depression: results from the ICEBERG study

BACKGROUND: The efficacy of esketamine nasal spray (NS) as a rapid-acting agent for treatment resistant depression (TRD) was demonstrated in comparisons with placebo, when both were given in addition to a newly initiated selective serotonin reuptake inhibitor (SSRI)/serotonin norepinephrine reuptake...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oliveira-Maia, Albino J., Rive, Benoit, Morrens, Joachim, Godinov, Yordan, Cabrieto, Jedelyn, Perualila, Nolen, Mulhern-Haughey, Siobhán
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Psychiatry
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10669145/ https://www.ncbi.nlm.nih.gov/pubmed/38025416 http://dx.doi.org/10.3389/fpsyt.2023.1250987

Ejemplares similares

ICEBERG study: an indirect adjusted comparison estimating the long-term benefit of esketamine nasal spray when compared with routine treatment of treatment resistant depression in general psychiatry
por: Oliveira-Maia, Albino J., et al.
Publicado: (2023)

Esketamine Nasal Spray Improves Rate and Time to Remission Versus Quetiapine Extended Release in Subgroups of Patients With Treatment Resistant Depression and Two or Three Plus Prior Treatment Failures: Results From ESCAPE-TRD, a Randomised Phase IIIb Trial
por: Young, A.H., et al.
Publicado: (2023)

Esketamine nasal spray shows higher remission and response rates over 32 weeks of treatment compared with quetiapine extended-release in patients with treatment resistant depression: Results from ESCAPE-TRD, a randomised, phase IIIb clinical trial
por: Reif, A., et al.
Publicado: (2023)

Benefit–Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment‐Resistant Depression
por: Katz, Eva G., et al.
Publicado: (2020)

Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression
por: Chen, Guang, et al.
Publicado: (2022)

Adjusted Comparison of Outcomes between Patients from CARTITUDE-1 versus Multiple Myeloma Patients with Prior Exposure to PI, Imid and Anti-CD-38 from a German Registry
por: Merz, Maximilian, et al.
Publicado: (2021)

Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program
por: Doherty, Teodora, et al.
Publicado: (2020)

Treatment Response of Add-On Esketamine Nasal Spray in Resistant Major Depression in Relation to Add-On Second-Generation Antipsychotic Treatment
por: Dold, Markus, et al.
Publicado: (2020)

Testing for the Presence of Correlation Changes in a Multivariate Time Series: A Permutation Based Approach
por: Cabrieto, Jedelyn, et al.
Publicado: (2018)

Detecting long-lived autodependency changes in a multivariate system via change point detection and regime switching models
por: Cabrieto, Jedelyn, et al.
Publicado: (2018)

Beyond the tip of the iceberg: direct and indirect effects of COVID-19
por: Kaczorowski, Janusz, et al.
Publicado: (2021)

ESKALE study, a French real-world study of esketamine nasal spray for patients with treatment-resistant depression
por: Ludovic, S., et al.
Publicado: (2022)

Urothelial toxicity of esketamine in the treatment of depression
por: Findeis, Hannelore, et al.
Publicado: (2020)

Esketamine/ketamine for treatment-resistant depression
por: Lacerda, Acioly L.T.
Publicado: (2020)

Esketamine hydrochloride for treatment-resistant depression
Publicado: (2021)

Managing dissociative symptoms following the use of esketamine nasal spray: a case report
por: Pereira, Sophia, et al.
Publicado: (2020)

Early Clinical Experiences of Esketamine Nasal Spray in the UK in Adults with Treatment-Resistant Major Depressive Disorder: Advisory Panel Recommendations
por: Young, Allan H, et al.
Publicado: (2023)

The role of intranasal esketamine in treatment-resistant depression
por: Fraga, A., et al.
Publicado: (2021)

Improvement of functional neurological disorder after administration of esketamine nasal spray: a case report
por: Vendrell-Serres, Júlia, et al.
Publicado: (2021)

Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials
por: Jones, Robyn R., et al.
Publicado: (2022)

Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study
por: Zaki, Naim, et al.
Publicado: (2023)

An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations
por: Chouaid, Christos, et al.
Publicado: (2023)

How effective are ketamine or esketamine in treatment-resistant depression?
por: Veluri, N., et al.
Publicado: (2021)

Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant
por: Jamieson, Carol, et al.
Publicado: (2023)

P922: ADJUSTED COMPARISONS OF CILTACABTAGENE AUTOLEUCEL WITH THERAPIES FROM REAL-WORLD CLINICAL PRACTICE: TWO-YEAR FOLLOW-UP ANALYSES FROM CARTITUDE-1 AND THE PROSPECTIVE LOCOMMOTION STUDY
por: Mateos, Maria-Victoria, et al.
Publicado: (2023)

Real-world approach to managing dysgeusia following the use of esketamine nasal spray: a case report
por: Bossaller, Nicholas A., et al.
Publicado: (2020)

P923: COMPARATIVE EFFECTIVENESS OF TALQUETAMAB VS REAL-WORLD PHYSICIAN’S CHOICE OF TREATMENT IN LOCOMMOTION AND MOMMENT FOR PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Einsele, Hermann, et al.
Publicado: (2023)

Social determinants and distance from certified treatment centers are associated with initiation of esketamine nasal spray among patients with challenging-to-treat major depressive disorder
por: Liberman, Joshua, et al.
Publicado: (2023)

Tip of the iceberg
por: Jacobsson, Richard
Publicado: (2004)

The nanny and the iceberg /
por: Dorfman, Ariel
Publicado: (1999)

Tip of the Iceberg
por: Sherlock, Fiona
Publicado: (2020)

The tip of the iceberg
por: Morales‐Camacho, Rosario M., et al.
Publicado: (2020)

Esketamine Nasal Spray for the Rapid Reduction of Depressive Symptoms in Major Depressive Disorder With Acute Suicidal Ideation or Behavior
por: Canuso, Carla M., et al.
Publicado: (2021)

Esketamine for treatment resistant depression: a trick of smoke and mirrors?
por: Gastaldon, C., et al.
Publicado: (2019)

The Patient’s Perspective on the Effects of Intranasal Esketamine in Treatment-Resistant Depression
por: Pepe, Maria, et al.
Publicado: (2023)

Use of Clinical Global Impressions-Severity (CGI-S) to Assess Response to Antidepressant Treatment in Patients with Treatment-Resistant Depression
por: Morrens, Joachim, et al.
Publicado: (2022)

Esketamine: new hope for the treatment of treatment-resistant depression? A narrative review
por: Salahudeen, Mohammed S, et al.
Publicado: (2020)

Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice
por: Mateos, Maria-Victoria, et al.
Publicado: (2022)

Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study
por: Castro, Meredith, et al.
Publicado: (2023)

Clinical characteristics of treatment-resistant depression in adults in Hungary: Real-world evidence from a 7-year-long retrospective data analysis
por: Döme, Péter, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_pt1q6rhuoug4rr2i09keusjo7d